Xeltis
Eindhoven
About Xeltis
A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for which clinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $253.5M
- Funding stage: Late Stage Venture
- Last round: Debt Financing (Dec 2025)
- Website: xeltis.com
- Phone: +31407517614
Industries & Categories
Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/xeltis-78383 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.